Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4031814 | 1.00 | HSD11B1 (0.54) | HSD11B1OPRM1CYP2D6MC4RMBTD1 | |
| SCHEMBL1586528 | 0.83 | CYP2D6 (0.70) | HSD11B1OPRM1CYP2D6MC4RCHRM2 | |
| SCHEMBL13283877 | 0.83 | HSD11B1 (0.52) | HSD11B1OPRM1CYP2D6MC4RCHRM2 | |
| SCHEMBL4601165 | 0.83 | CYP2D6 (0.70) | HSD11B1OPRM1CYP2D6MC4RCHRM2 | |
| SCHEMBL8099850 | 0.83 | CYP2D6 (0.70) | HSD11B1OPRM1CYP2D6MC4RCHRM2 | |
| SCHEMBL19613500 | 0.83 | CYP2D6 (0.70) | HSD11B1OPRM1CYP2D6MC4RCHRM2 | |
| SCHEMBL3041069 | 0.82 | CYP2D6 (0.52) | HSD11B1OPRM1CYP2D6MC4RMBTD1 | |
| SCHEMBL4248140 | 0.82 | CYP2D6 (0.52) | HSD11B1OPRM1CYP2D6MC4RMBTD1 | |
| SCHEMBL12685149 | 0.81 | HSD11B1 (0.54) | HSD11B1OPRM1CYP2D6MC4RCHRM2 | |
| SCHEMBL3715276 | 0.81 | HSD11B1 (0.54) | HSD11B1OPRM1CYP2D6MC4RCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | HSD11B1 3508/4885OPRM1 29/4885CYP2D6 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.